Trial Profile
Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 Apr 2021 Planned End Date changed from 1 Jul 2022 to 17 Oct 2018.
- 01 Apr 2021 Planned primary completion date changed from 1 Jul 2022 to 17 Oct 2018.
- 01 Oct 2018 Status changed to withdrawn prior to enrolment.